Eli Lilly and Novo Nordisk leaders share their India strategies for weight-loss drugs. They focus on pricing, market expansion, and countering generics after semaglutide's patent ends. Both companies aim to increase patient access to their innovative therapies. They are working with partners to reach more people across India. This ensures their medicines benefit a wider population.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gjzOyd6
via IFTTT
No comments:
Post a Comment